2023 News Releases
Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2023 Financial Results
LOS ANGELES, Calif., Oct. 19, 2023 - Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical
company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, November 2, 2023,
following the release of its third quarter 2023 financial results.
The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international).
Please dial in at least 10 minutes in advance and inform the operator that you would like to join the
“Puma Biotechnology Conference Call.” A live webcast of the conference call and presentation slides
may be accessed on the Investors section of the Puma Biotechnology website at
https://www.pumabiotechnology.com. A replay of the call will be available shortly after completion of
the call and will be archived on Puma’s website for 90 days.
About Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and
commercialization of innovative products to enhance cancer care. Puma in-licensed the global development
and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357.
Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant
treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant
trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In
February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the
treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two
or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing
authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients
with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less
than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX® is a registered
trademark of Puma Biotechnology, Inc.
In September 2022, Puma entered into an exclusive license agreement for the development and
commercialization of the anti-cancer drug alisertib, a selective, small molecule, orally administered
inhibitor of aurora kinase A. Initially, Puma intends to focus the development of alisertib on the
treatment of small cell lung cancer and breast cancer.
Further information about Puma Biotechnology may be found at https://www.pumabiotechnology.com.
Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500
David Schull or Olipriya Das, Russo Partners, +1 212 845 4200
# # # # #
Back to 2023 News Releases
Puma Biotechnology, Inc.
10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024